Information Provided By: 
Fly News Breaks for March 13, 2018
ADXS
Mar 13, 2018 | 04:54 EDT
Cantor Fitzgerald analyst Mara Goldstein lowered his price target for Advaxis to $5 after a clinical hold was placed on the Phase I/II AXAL plus durvalumab trial. The analyst, however, thinks it is "very possible" that the hold will be resolved. Further, Advaxis has sufficient capital into 2019, which is a "counterpoint to the clinical hold," Goldstein tells investors in a research note. She keeps an Overweight rating on Advaxis shares.
News For ADXS From the Last 2 Days
There are no results for your query ADXS
